Exact Sciences UK, Ltd. news
- Updated RxPONDER study analysis provides further evidence that the test identifies the majority of women with early-stage, node-positive breast cancer who can avoid chemotherapy
Exact Sciences Corp. (NASDAQ: EXAS), a global leader in cancer diagnostics, today announced the presentation of new data at the 2021 San Antonio Breast Cancer Symposium (SABCS) supporting the clinical value of the Oncotype DX Breast Recurrence Score test. New analyses presented
- RxPONDER, an independent study led by SWOG Cancer Research Network, demonstrates that guiding treatment with Oncotype DX test can spare chemotherapy use in majority of postmenopausal women
- Results have already led to updated NCCN Guidelines® for breast cancer
- New RxPONDER results to be featured in oral presentation at 2021 San Antonio Breast Cancer Symposium (SABCS)
Exact Sciences Corp. (NASDAQ: EXAS) today announced that data from the Rx for Pos
- Improved quality of care and significant cost savings using the test to guide adjuvant chemotherapy treatment
- Analysis based on first results from the independent RxPONDER study which identified the majority of women with one to three positive nodes who receive no benefit from chemotherapy
Exact Sciences today announced results from a health economic analysis of the Oncotype DX Breast Recurrence Score® test, accepted at the 2021 American Society of Clinica
Exact Sciences today announced that its Oncotype DX Breast Recurrence Score test has been recognised as the only test that can be used for prediction of chemotherapy benefit in early-stage breast cancer patients with 1-3 positive axillary lymph nodes, including micro metastases, by the National Comprehensive Cancer Network (NCCN)ii in its updated guidelines for breast cancer. iii The Oncotype DX test is now the only test classified as “preferred” with the highest level of evidence
- First results from the independent SWOG Cancer Research Network-led Phase III study to be presented at the 2020 San Antonio Breast Cancer Symposium
- RxPONDER results from over 5,000 women likely to transform the treatment of node-positive breast cancer, as the TAILORx study did in node-negative disease
Exact Sciences Corp. (NASDAQ: EXAS) today announced that data from the Rx for Positive Node, Endocrine Responsive Breast Cancer, or RxPONDER, trial successfully
- Study results presented at ASCO20 showed that the Recurrence Score results on core biopsies predict the likelihood of response to neoadjuvant chemotherapy
- Results are particularly relevant in the context of the Covid-19 pandemic which is causing the delay of elective surgeries across health systems worldwide
Exact Sciences Corp. today announced results from three studies of the Oncotype DX Breast Recurrence Score test, presented at the virtua
- Data obtained in real-life setting from more than 800 patients with node-negative or nodepositive early-stage breast cancer highlight the test’s impact on clinical practice with chemotherapy-sparing effect
- Publication of landmark TAILORx study results led to greater reduction in chemotherapy recommendations
Exact Sciences Corp. today announced results from a prospective clinical survey of the Oncotype DX Breast Recurrence Score test, ac
- TAILORx Study Featured in William L. McGuire Memorial Lecture Award at 2019 San Antonio Breast Cancer Symposium
- New Publication of Long-term Data from Real-world Clinical Practice Confirms Conclusions of TAILORx
Exact Sciences Corp. (NASDAQ: EXAS) today announced new outcomes data from two large population-based studies1,2 presented at the 2019 San Antonio Breast Cancer Symposium (SABCS). The real-world evidence suggests that use of the Oncot
- Clinical Outcomes in Patients with High Recurrence Score Results
- Presented in Oral Session at ESMO 2019 Congress
- With Fourth Peer-Reviewed Publication, TAILORx Continues to Elevate
- Oncotype DX Test to a New Global Standard
Genomic Health on Monday announced results from a new analysis of the Trial Assigning IndividuaLised Options for Treatment (Rx), or TAILORx, which reinforce the unique value of the Oncotype DX Breast Recurrence Score test